Sind Mistelpräparate bei malignen Lymphomen und Leukämien kontraindiziert?

Abstract: Especially conventional oncologists often object that the growth of lymphoma or leukemia could be stimulated by mistletoe therapy. This objection is based on immunologic hypotheses and the incomplete knowledge of mistletoe pharmacology. Experimental results on various lymphoma and leukemia cell cultures demonstrate a strong inhibition but no stimulation of malignant cell growth by the mistletoe preparation HELIXOR®. Even if this cytotoxic and cytostatic effect is neutralized by antibodies against mistletoe lectins, there is no proof of stimulation.Above all, there are documentations of good clinical results of an additive treatment with HELIXOR® in patients with chronic leukemias, low malignant Non-Hodgkin lymphoma, multiple myeloma and Hodgkin's disease. A clinical trial in patients with CML shows a distinct prolongation of median survival when using HELIX0R® in addition to chemotherapy. However, is must be emphasized, that HELIXOR® application systemic malignant diseases is very different from its use in common cancer, in order to avoid a stimulation of inflammatory reactions: use of needle tree instead of decid-uous tree mistletoes, very cautious dose increase and daily injections without pauses. As a rule, mistletoe therapy is used simultaneously to the conventional cancer treatments but not as monotherapy.

Keyword(s): Misteltherapie

Zurück | Weiter